Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third ...

HYDERABAD: Degrowth in its US formulations business dragged down Aurobindo Pharma’s consolidated net profits for the third ...

Aurobindo Pharma's net profit declines 10% due to lower U.S. formulations revenue, but revenue from operations increases.

The Board of Aurobindo Pharma at its meeting held on 06 February 2025 has approved to enter into a power purchase agreement with Swarnaaskshu Solar Power (Swarnaaskshu), a company under incorporation, ...

Hyderabad: CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, has announced that the Committee for ...

Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.